On the stock market since 2009, it operates in the world of health and science. It has 939 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Average growth of 7% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $154.5M a year. A small number, but proof the product has real buyers.
A loss of $4.2M against $154.5M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, CJJD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CJJD is a high-risk stock — not yet profitable, and its future rides on its product catching on.